A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Anxiety Disorders

Treatments: Drug: MK0777

Study type: Interventional

Funder types: Industry

Identifiers

NCT00543920

0777-020

2007_633

Details and patient eligibility

About

The study will look at the effect of MK0777on reducing anxiety in subjects with general anxiety disorder.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Enrollment: 60 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of General Anxiety Order

Exclusion criteria

• Women who are pregnant or breast-feeding
• History of severe drug reaction
• History of severe drug withdrawal symptoms such as seizures or delirium
• Disease of cardiovascular system
• Disease of the liver, kidneys, endocrine system, metabolic system or eyes
• History of seizures or seizure disorder
• History of drug or alcohol abuse

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind